Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2005 Oct 5;7(2):E390–E407. doi: 10.1208/aapsj070240

Modeling and simulation of adherence: Approaches and applications in therapeutics

Leslie A Kenna 1,✉, Line Labbé 3, Jeffrey S Barrett 4, Marc Pfister 5
PMCID: PMC2750977  PMID: 16353919

Abstract

Partial adherence with a prescribed or randomly assigned dose gives rise to unintended variability in actual drug exposure in clinical practice and during clinical trials. There are tremendous costs associated with incomplete and/or improper drug intake—to both individual patients and society as a whole. Methodology for quantifying the relation between adherence, exposure and drug response is an area of active research. Modeling and statistical approaches have been useful in evaluating the impact of adherence on therapeutics and in addressing the challenges of confounding and measurement error which arise in this context. This paper reviews quantitative approaches to using adherence information in improving therapeutics. It draws heavily on applications in the area of HIV pharmacology.

Keywords: adherence, modeling, simulation, PK/PD, NONMEM

Full Text

The Full Text of this article is available as a PDF (2.2 MB).

References

  • 1.Vrijens B, Tousset E, Gaillard P, Metry J, Urquhart J. Major features of dose omissions in 87 ambulatory drug trials. Clin Pharmacol Ther. 2005;77:99–99. [Google Scholar]
  • 2.Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm. 1991;48:1978–1988. [PubMed] [Google Scholar]
  • 3.Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York: Raven Press Ltd; 1991. [Google Scholar]
  • 4.Didlake RH, Dreyfus K, Kermanet RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc. 1988;20(suppl 3):63–69. [PubMed] [Google Scholar]
  • 5.Kastrissios H, Blaschke TF. Therapeutic implications of nonadherence with antiretroviral drug regimens. HIV. 1998;8:24–28. [Google Scholar]
  • 6.Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J. 1992;68(suppl 3):S49–S59. [PubMed] [Google Scholar]
  • 7.Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345–356. doi: 10.2165/00003088-199732050-00001. [DOI] [PubMed] [Google Scholar]
  • 8.Hong JH, Sumrani N, Delaney V, et al. Causes of late renal allograft failure in the ciclosporin era. Nephron. 1992;62:272–279. doi: 10.1159/000187058. [DOI] [PubMed] [Google Scholar]
  • 9.Dunn J, Golden D, Buren CT, et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation. 1990;49:349–353. doi: 10.1097/00007890-199002000-00024. [DOI] [PubMed] [Google Scholar]
  • 10.Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet. 1994;27:202–215. doi: 10.2165/00003088-199427030-00004. [DOI] [PubMed] [Google Scholar]
  • 11.Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385–391. doi: 10.1016/S0895-4356(97)00041-3. [DOI] [PubMed] [Google Scholar]
  • 12.Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273–3277. doi: 10.1001/jama.261.22.3273. [DOI] [PubMed] [Google Scholar]
  • 13.Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics. 1999;15:423–434. doi: 10.2165/00019053-199915050-00001. [DOI] [PubMed] [Google Scholar]
  • 14.Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994;330:1179–1184. doi: 10.1056/NEJM199404283301702. [DOI] [PubMed] [Google Scholar]
  • 15.Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090. doi: 10.1016/S0149-2918(99)80026-5. [DOI] [PubMed] [Google Scholar]
  • 16.Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG) AIDS Care. 2000;12:255–266. doi: 10.1080/09540120050042891. [DOI] [PubMed] [Google Scholar]
  • 17.Klerk E, Linden SJ. Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol. 1996;35:60–65. doi: 10.1093/rheumatology/35.1.60. [DOI] [PubMed] [Google Scholar]
  • 18.Lee JY, Kusek JW, Greene PF, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996;9:719–725. doi: 10.1016/0895-7061(96)00056-8. [DOI] [PubMed] [Google Scholar]
  • 19.Bloch M, Gur E, Shalev AY. Hypouricemic effect of zuclopenthixol: a potential marker of drug compliance? Psychopharmacology (Berl) 1992;109:377–378. doi: 10.1007/BF02245887. [DOI] [PubMed] [Google Scholar]
  • 20.Kapur S, Ganguli R, Ulrich R, et al. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr Res. 1991;6:49–53. doi: 10.1016/0920-9964(91)90020-R. [DOI] [PubMed] [Google Scholar]
  • 21.Hardy E, Kumar S, Peaker S, et al. A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release ‘therapeutic drug’ (metoprolol, Metoros) in reflecting incomplete compliance by volunteers. Br J Clin Pharmacol. 1990;30:437–441. doi: 10.1111/j.1365-2125.1990.tb03795.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Maenpaa H, Javela K, Pikkarainen JH, et al. Minimal doses of digoxin: a new marker for compliance to medication. Eur Heart J. 1987;8(suppl 1):31–37. doi: 10.1093/eurheartj/8.suppl_i.31. [DOI] [PubMed] [Google Scholar]
  • 23.Pekovic V, Mayanja H, Vjecha M, et al. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. J Clin Epidemiol. 1998;51:597–607. doi: 10.1016/S0895-4356(98)00033-X. [DOI] [PubMed] [Google Scholar]
  • 24.Lu J, Gries JM, Verotta D, et al. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance. J Pharmacokinet Pharmacodyn. 2001;28:343–362. doi: 10.1023/A:1011582713692. [DOI] [PubMed] [Google Scholar]
  • 25.Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods. AIDS Read. 1999;9:329–338. [PubMed] [Google Scholar]
  • 26.Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. Boca Raton, FL: CRC Press; 1998. [Google Scholar]
  • 27.Kenna LA, Sheiner LB. Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods. Stat Med. 2004;23:3561–3580. doi: 10.1002/sim.1830. [DOI] [PubMed] [Google Scholar]
  • 28.Kenna LA. Estimating treatment effect in the presence of non-compliance measured with error: power, precision and robustness of data analysis methods. San Francisco, CA: University of California San Francisco; 2001. [DOI] [PubMed] [Google Scholar]
  • 29.Catania JA, Binson D, Canchola J, et al. Effects of interviewer gender, interviewer choice, and item wording on response to questions concerning sexual behavior. Public Opinion Quarterly. 1996;60:345–375. doi: 10.1086/297758. [DOI] [Google Scholar]
  • 30.Kaplan RM, Simon HJ. Compliance in medical care: reconsideration of self-predictions. Ann Behav Med. 1990;12:66–71. doi: 10.1207/s15324796abm1202_2. [DOI] [Google Scholar]
  • 31.Hyland ME, Kenyon CA, Allen R, et al. Diary keeping in asthma: comparison of written and electronic methods. BMJ. 1993;306:487–489. doi: 10.1136/bmj.306.6876.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366. doi: 10.1097/00002030-200003100-00008. [DOI] [PubMed] [Google Scholar]
  • 33.Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990;150:1377–1378. doi: 10.1001/archinte.150.7.1377. [DOI] [PubMed] [Google Scholar]
  • 34.Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968–977. doi: 10.7326/0003-4819-134-10-200105150-00011. [DOI] [PubMed] [Google Scholar]
  • 35.Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Control Clin Trials. 1997;18:187–203. doi: 10.1016/S0197-2456(96)00235-8. [DOI] [PubMed] [Google Scholar]
  • 36.Robins JM. Correction for non-compliance in equivalence trials. Stat Med. 1998;17:269–302. doi: 10.1002/(SICI)1097-0258(19980215)17:3<269::AID-SIM763>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  • 37.Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcome in randomized controlled trials. Stat Med. 1998;17:341–355. doi: 10.1002/(SICI)1097-0258(19980215)17:3<341::AID-SIM766>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 38.Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc. 1991;86:9–22. doi: 10.2307/2289707. [DOI] [Google Scholar]
  • 39.Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther. 1995;57:6–15. doi: 10.1016/0009-9236(95)90260-0. [DOI] [PubMed] [Google Scholar]
  • 40.Angrist JD, Imbens GW, Rubin DR. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;91:444–472. doi: 10.2307/2291629. [DOI] [Google Scholar]
  • 41.Albert JM, Demets DL. On a model-based approach to estimating efficacy in clinical trials. Stat Med. 1994;13:2323–2335. doi: 10.1002/sim.4780132204. [DOI] [PubMed] [Google Scholar]
  • 42.Jonsson EN, Wade JR, Almqvist G, et al. Discrimination between rival dosing histories. Pharm Res. 1997;14:984–991. doi: 10.1023/A:1012184808192. [DOI] [PubMed] [Google Scholar]
  • 43.Cheng CW, Woo KS, Chan JC, et al. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol. 2004;58:528–535. doi: 10.1111/j.1365-2125.2004.02202.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002;113:625–629. doi: 10.1016/S0002-9343(02)01303-7. [DOI] [PubMed] [Google Scholar]
  • 45.Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208–211. doi: 10.5694/j.1326-5377.1996.tb94138.x. [DOI] [PubMed] [Google Scholar]
  • 46.Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care. 1999;5:437–444. [PubMed] [Google Scholar]
  • 47.Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993–1998. Br J Clin Pharmacol. 2002;53:375–378. doi: 10.1046/j.1365-2125.2002.01563.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hughes DA, Walley T. Predicting “real world” effectiveness by integrating adherence with pharmacodynamic modeling. Clin Pharmacol Ther. 2003;74:1–8. doi: 10.1016/S0009-9236(03)00091-2. [DOI] [PubMed] [Google Scholar]
  • 49.Williams-Deane M, Potter LS. Current oral contraceptive use instructions: An analysis of patient package inserts. Fam Plann Perspect. 1992;24:111–115. doi: 10.2307/2135540. [DOI] [PubMed] [Google Scholar]
  • 50.Urquhar J. Erratic patient compliance with prescribed drug regiments: target for drug delivery systems. Clin Pharmacol Ther. 2000;67:331–334. doi: 10.1067/mcp.2000.105582. [DOI] [PubMed] [Google Scholar]
  • 51.Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2002;88:203–206. doi: 10.1136/heart.88.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther. 1994;1:260–267. doi: 10.1097/00045391-199412000-00003. [DOI] [PubMed] [Google Scholar]
  • 53.Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Br J Clin Pharmacol. 1982;13(suppl 2):345S–351S. doi: 10.1111/j.1365-2125.1982.tb01939.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Vaur L, Dutrey-Dupagne C, Boussac J, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol. 1995;26:127–131. doi: 10.1097/00005344-199507000-00020. [DOI] [PubMed] [Google Scholar]
  • 55.Leenen FH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after ‘missed doses’ of calcium antagonist with long (amlodipine) vs short (diltiazem), elimination half-life. Br J Clin Pharmacol. 1996;41:83–88. doi: 10.1111/j.1365-2125.1996.tb00164.x. [DOI] [PubMed] [Google Scholar]
  • 56.Mallion JM, Meilhac B, Tremel F, et al. Use of a microprocessor-equipped tablet box in monitoring compliance with antihypertensive treatment. J Cardiovasc Pharmacol. 1992;19(suppl 2):S41–S48. doi: 10.1097/00005344-199219002-00011. [DOI] [PubMed] [Google Scholar]
  • 57.Lee SY, Song XY. Bayesian analysis of structural equation models with dichotomous variables. Stat Med. 2003;22:3073–3088. doi: 10.1002/sim.1544. [DOI] [PubMed] [Google Scholar]
  • 58.Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1997–1983. doi: 10.1001/jama.279.24.1977. [DOI] [PubMed] [Google Scholar]
  • 59.Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996;276:1955–1956. doi: 10.1001/jama.276.24.1955. [DOI] [PubMed] [Google Scholar]
  • 60.Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA. 1998;279:1984–1991. doi: 10.1001/jama.279.24.1984. [DOI] [PubMed] [Google Scholar]
  • 61.Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925–1932. doi: 10.1097/00002030-200309050-00011. [DOI] [PubMed] [Google Scholar]
  • 62.Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47:130–137. doi: 10.1128/AAC.47.1.130-137.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Urquhart J. Non-compliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS, editors. Novel Drug Delivery and Its Therapeutic Applications. Chichester, UK: John Wiley & Sons; 1989. pp. 127–137. [Google Scholar]
  • 64.Kastrissios H, Suarez JR, Katzenstein D, et al. Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998;12:2295–2303. doi: 10.1097/00002030-199817000-00011. [DOI] [PubMed] [Google Scholar]
  • 65.Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm. 1996;24:265–282. doi: 10.1007/BF02353671. [DOI] [PubMed] [Google Scholar]
  • 66.Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med. 1998;17:2313–2333. doi: 10.1002/(SICI)1097-0258(19981030)17:20<2313::AID-SIM935>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 67.Vrijens B. Analyzing time-varying patterns of human exposure to xenobiotics and their biomedical impact. Ghent, Belgium: University of Ghent; 2002. [Google Scholar]
  • 68.Labbé L, Hammer SM, Mellors JW, et al. A Markov model for the effect of covariates including drug adherence on longitudinal viral response in HIV patients. Clin Pharmacol Ther. 2004;75:90–90. [Google Scholar]
  • 69.Labbé L, Verotta D. A non-linear mixed effect dynamic model using adherence to treatment to describe long-term therapy outcome in HIV-patients. Clin Pharmacol Ther. 2005;77:90–90. doi: 10.1016/j.clpt.2004.09.007. [DOI] [PubMed] [Google Scholar]
  • 70.Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis. Appl Stats. 1994;43:49–93. doi: 10.2307/2986113. [DOI] [Google Scholar]
  • 71.Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn. 2003;30:83–103. doi: 10.1023/A:1023249510224. [DOI] [PubMed] [Google Scholar]
  • 72.Noordmohamed SE, Henry WK, Rhame FS, et al. Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother. 1995;39:2792–2797. doi: 10.1128/aac.39.12.2792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003;115:632–641. doi: 10.1016/j.amjmed.2003.07.007. [DOI] [PubMed] [Google Scholar]
  • 74.Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87. doi: 10.7326/0003-4819-131-2-199907200-00002. [DOI] [PubMed] [Google Scholar]
  • 75.Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in “revolving door” schizophrenic patients. J Clin Psychiatry. 1996;57:337–345. [PubMed] [Google Scholar]
  • 76.Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150:1509–1510. doi: 10.1001/archinte.150.7.1509. [DOI] [PubMed] [Google Scholar]
  • 77.Waeber B, Leonetti G, Kolloch R, et al. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens. 1999;17:1041–1045. doi: 10.1097/00004872-199917070-00022. [DOI] [PubMed] [Google Scholar]
  • 78.Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol. 1997;37:451–475. doi: 10.1146/annurev.pharmtox.37.1.451. [DOI] [PubMed] [Google Scholar]
  • 79.Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523. doi: 10.1016/0002-9394(86)90939-6. [DOI] [PubMed] [Google Scholar]
  • 80.Peck CC. Non-compliance and clinical trials: regulatory perspectives. In: Metry JM, Meyer UA, editors. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley & Sons; 1999. pp. 97–102. [Google Scholar]
  • 81.Hasford J. Design and analysis of clinical trials of compliance. In: Metry JM, Meyer UA, editors. Drug Regimen Compliance: Issues in Clinical Trials and Patient Management. Chichester, UK: John Wiley & Sons; 1999. pp. 23–40. [Google Scholar]
  • 82.Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2000;2:CD000011–CD000011. doi: 10.1002/14651858.CD000011. [DOI] [PubMed] [Google Scholar]
  • 83.Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2001;4:CD003343–CD003343. doi: 10.1002/14651858.CD003343. [DOI] [PubMed] [Google Scholar]
  • 84.Barker J, Millard J. Directly observed therapy and treatment adherence. Lancet. 2000;356:1030–1. doi: 10.1016/S0140-6736(05)72650-7. [DOI] [PubMed] [Google Scholar]
  • 85.Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Info J. 1998;22:363–378. [Google Scholar]
  • 86.Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275–291. doi: 10.1016/S0009-9236(97)90160-0. [DOI] [PubMed] [Google Scholar]
  • 87.Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol. 2005;96:228–234. doi: 10.1111/j.1742-7843.2005.pto960313.x. [DOI] [PubMed] [Google Scholar]
  • 88.Lasagn L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, editors. Compliance in Medical Practice and Clinical Trials, JA. New York: Raven Press; 1991. pp. 393–403. [Google Scholar]
  • 89.Morris SE, Groom GV, Cameron ED, et al. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill (‘Microgynon 30’) omission. Contraception. 1979;20:61–69. doi: 10.1016/0010-7824(79)90045-3. [DOI] [PubMed] [Google Scholar]
  • 90.Chowdhury V, Joshi UM, Gopalkrishna K, et al. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception. 1980;22:241–247. doi: 10.1016/S0010-7824(80)80003-5. [DOI] [PubMed] [Google Scholar]
  • 91.Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of “missing the pill”. Contraception. 1982;26:545–566. doi: 10.1016/0010-7824(82)90131-7. [DOI] [PubMed] [Google Scholar]
  • 92.Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception. 1984;29:437–446. doi: 10.1016/0010-7824(84)90017-9. [DOI] [PubMed] [Google Scholar]
  • 93.Landgren BM, Csemiczky G. The effect of follicular growth and luteal function of “missing the pill”. A comparison between a monophasic and a triphasic combined oral contraceptive. Contraception. 1991;43:149–159. doi: 10.1016/0010-7824(91)90042-E. [DOI] [PubMed] [Google Scholar]
  • 94.Cross JT, Lee HD, Nelson JS, et al. One in five marketed drugs undergoes a dosage change: 1980–1999. Clin Pharmacol Ther. 2001;69:63–63. [Google Scholar]
  • 95.Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
  • 96.Fremont-Smith K, Kravitz GR, Bush T, et al. Adverse drug reactions in hospitalized patients. J Am Stat Assoc. 1998;280:1741–1741. [Google Scholar]
  • 97.Burney KD, Krishnan K, Ruffin MT, et al. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Arch Farm Med. 1996;5:297–300. doi: 10.1001/archfami.5.5.297. [DOI] [PubMed] [Google Scholar]
  • 98.Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004–1006. doi: 10.7326/0003-4819-134-10-200105150-00015. [DOI] [PubMed] [Google Scholar]
  • 99.Meredith PA, Elliott HL. Therapeutic coverage: reducing the risks of partial compliance. Br J Clin Pract. 1994;73:13–17. [PubMed] [Google Scholar]
  • 100.Detry JM. Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient Compliance. Clin Cardiol. 1994;17(suppl 3):III12–III16. [PubMed] [Google Scholar]
  • 101.Urquhart J, Klerk E. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. Stat Med. 1998;17:251–267. doi: 10.1002/(SICI)1097-0258(19980215)17:3<251::AID-SIM762>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES